News

The sales in the first nine months of 2010 were $1,216,019 compared to $911,543 in the corresponding previous year period. BioSyent incurred a loss of $31,987 in the

The decrease in net revenue was due to a planned reduction in sales to certain distributors with low gross profit margins, as the company made a shift in

Almac said that assembling regional packs results in one pack being available for as many as five markets, as country specific information is applied to the ‘Blue Box’

Nintex claimed that its products which are designed to streamline standard business activities, surface valuable information, encourage and enable collaboration, and empower business users and IT professionals alike,

The QTDP program was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. Glycotex said that GLYC-101 is being developed to stimulate

The investigational new drug application is held by GSK. The Vivalis and GSK global collaboration and license agreement aims to develop cell-based manufacturing of seasonal and pandemic human

In the statement of intent, Eisai agreed to produce and supply to WHO free of charge up to 2.2 billion 100mg tablets of diethylcarbamazine (generic name, DEC), a

The contract will see PRECOS provide clinical tumour material, tumour model development, target validation and drug efficacy work to support Janssen’s oncology drug discovery, development and biomarker programmes.

Executed in August 2008, the agreement allows Roche to develop hepatitis C viral (HCV) compounds while using Metabasis’ liver-targeting technology. Earlier, in April Roche has paid $6.5m payment